Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Corcept Therapeutics
(NQ:
CORT
)
22.48
-0.52 (-2.26%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,087,749
Open
23.00
Bid (Size)
22.11 (1)
Ask (Size)
23.39 (1)
Prev. Close
23.00
Today's Range
22.05 - 23.29
52wk Range
20.87 - 34.27
Shares Outstanding
115,926,629
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
Today 16:05 EDT
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Mid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study, FDA Application Submission Expected This Quarter
April 22, 2024
Insights from Corcept Therapeutics' Phase 3 GRACE trial results for endogenous Cushing's syndrome. Discover rapid improvements in hypertension and hyperglycemia without adverse effects. Join us for the...
Via
Benzinga
Exposures
Product Safety
Performance
YTD
-6.95%
-6.95%
1 Month
-8.84%
-8.84%
3 Month
-4.10%
-4.10%
6 Month
-19.86%
-19.86%
1 Year
-0.09%
-0.09%
More News
Read More
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
April 22, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.
April 19, 2024
Via
Chartmill
Recap: Corcept Therapeutics Q4 Earnings
February 15, 2024
Via
Benzinga
Earnings Scheduled For February 15, 2024
February 15, 2024
Via
Benzinga
Earnings Preview: Corcept Therapeutics
February 14, 2024
Via
Benzinga
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
April 15, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
April 08, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
April 01, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Despite its growth, NASDAQ:CORT remains within the realm of affordability.
January 03, 2024
Via
Chartmill
Investors seeking growth at a reasonable cost should explore NASDAQ:CORT.
March 29, 2024
Via
Chartmill
Don't overlook NASDAQ:CORT—a stock with solid growth prospects and a reasonable valuation.
March 07, 2024
Via
Chartmill
What's Going On With Stress Hormone Modulator-Focused Corcept Therapeutics' Stock Friday?
February 16, 2024
Via
Benzinga
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
February 15, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
February 15, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.
February 14, 2024
Via
Chartmill
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call
February 08, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Appoints Roberto Vieira as President, Oncology
January 29, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.
January 24, 2024
Via
Chartmill
Archer-Daniels-Midland, B. Riley Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session
January 22, 2024
Via
Benzinga
Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program
January 08, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Crude Oil Down 2%; Tesla Deliveries Top Estimates
January 02, 2024
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
January 02, 2024
Via
Benzinga
Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
January 02, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.